Using the latest technologies from fields such as immunology, microbiology, and epidemiology, we lead collaborative research projects designed to identify and study safe and effective vaccines and treatments for infectious illnesses of public health importance (including COVID-19, influenza, and mpox). We also seek to develop vaccines for noninfectious conditions including cancers, autoimmune disorders, brain conditions, and chronic diseases.

Our goals reach beyond just discovering the next vaccine. We care deeply about protecting public health and collaborate with communities to improve how we communicate information about vaccines and, more broadly, clinical trial research. We aim to increase access to care and combat vaccine hesitancy in New York City and globally.

With our expertise and resources, the Vaccine Center can respond immediately to public health emergencies, such as the COVID-19 pandemic that hit New York City in early 2020 and the mpox outbreak in 2022, by launching important clinical trials and studies.

In 2020, the Vaccine Center was established as a Vaccine and Treatment Evaluation Unit (VTEU) by the National Institute of Allergy and Infectious Diseases (NIAID). We are honored to be part of the Infectious Diseases Clinical Research Consortium, a clinical trials network made up of 10 VTEU sites nationwide.